1. Home
  2. RM vs CAPR Comparison

RM vs CAPR Comparison

Compare RM & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RM
  • CAPR
  • Stock Information
  • Founded
  • RM 1987
  • CAPR 2005
  • Country
  • RM United States
  • CAPR United States
  • Employees
  • RM N/A
  • CAPR N/A
  • Industry
  • RM Finance: Consumer Services
  • CAPR Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • RM Finance
  • CAPR Health Care
  • Exchange
  • RM Nasdaq
  • CAPR Nasdaq
  • Market Cap
  • RM 414.8M
  • CAPR 324.6M
  • IPO Year
  • RM 2012
  • CAPR N/A
  • Fundamental
  • Price
  • RM $43.75
  • CAPR $6.28
  • Analyst Decision
  • RM Hold
  • CAPR Strong Buy
  • Analyst Count
  • RM 2
  • CAPR 8
  • Target Price
  • RM $30.00
  • CAPR $24.75
  • AVG Volume (30 Days)
  • RM 52.0K
  • CAPR 1.4M
  • Earning Date
  • RM 07-30-2025
  • CAPR 08-11-2025
  • Dividend Yield
  • RM 2.74%
  • CAPR N/A
  • EPS Growth
  • RM 35.30
  • CAPR N/A
  • EPS
  • RM 3.47
  • CAPR N/A
  • Revenue
  • RM $591,436,000.00
  • CAPR $13,392,150.00
  • Revenue This Year
  • RM $16.20
  • CAPR N/A
  • Revenue Next Year
  • RM $7.43
  • CAPR $6,061.53
  • P/E Ratio
  • RM $12.63
  • CAPR N/A
  • Revenue Growth
  • RM 7.19
  • CAPR N/A
  • 52 Week Low
  • RM $25.41
  • CAPR $3.98
  • 52 Week High
  • RM $43.91
  • CAPR $23.40
  • Technical
  • Relative Strength Index (RSI)
  • RM 82.31
  • CAPR 36.33
  • Support Level
  • RM $36.88
  • CAPR $6.17
  • Resistance Level
  • RM $42.05
  • CAPR $7.30
  • Average True Range (ATR)
  • RM 1.29
  • CAPR 0.43
  • MACD
  • RM 0.49
  • CAPR -0.11
  • Stochastic Oscillator
  • RM 98.79
  • CAPR 4.53

About RM Regional Management Corp.

Regional Management Corp is a diversified consumer finance company that provides installment loan products to customers with limited access to consumer credit from banks, thrifts, credit card companies, and other lenders. It is engaged in consumer finance. The company has the core products which are small and large installment loans. The company also offers optional payment and collateral protection insurance. The company's principal source of revenue is interest and fee income on outstanding loans.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: